Crinetics Pharmaceuticals (CRNX) Osake Kurssi

Crinetics Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Crinetics Pharmaceuticals Inc in the market are other pharmaceutical companies specializing in the development and commercialization of novel therapeutics. These competitors include established players like Pfizer Inc., Merck & Co. Inc., and Novartis AG, as well as emerging biotechnology companies such as Amgen Inc., Gilead Sciences Inc., and Vertex Pharmaceuticals Incorporated. Crinetics Pharmaceuticals Inc faces competition in specific therapeutic areas where its pipeline products and drug candidates are positioned, such as endocrine disorders and rare diseases. As a dynamic pharmaceutical company, Crinetics Pharmaceuticals Inc aims to differentiate itself through innovative research, clinical advancements, and strategic partnerships.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company founded in 2008. The company is focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. With a dedicated team of scientists and researchers, Crinetics Pharmaceuticals is committed to advancing innovative treatments that address unmet medical needs. Since its inception, the company has made significant strides in its pipeline, including the development of CRN00808, a potential treatment for acromegaly and neuroendocrine tumors. Crinetics Pharmaceuticals continues to push the boundaries of medical research and aims to improve the lives of patients affected by rare endocrine disorders.

Crinetics Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in July 2018, raising $108 million in gross proceeds. In February 2020, Crinetics Pharmaceuticals announced positive topline results from its Phase 2 ACROBAT Edge clinical trial, evaluating the effectiveness of its oral nonpeptide somatostatin receptor type 2 agonist in the treatment of acromegaly, a rare hormonal disorder. Moreover, the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate, paltusotine, in April 2021, for the treatment of patients with acromegaly and carcinoid syndrome. These achievements highlight Crinetics Pharmaceuticals' successful advancement in drug development and dedication to addressing unmet medical needs.

Crinetics Pharmaceuticals Inc primarily operates in the United States.

Crinetics Pharmaceuticals Inc represents a strong commitment to scientific innovation and the development of novel therapeutics. The company's corporate philosophy is centered around addressing unmet medical needs, improving patient outcomes, and providing value to stakeholders. Crinetics Pharmaceuticals Inc values collaboration, research excellence, and integrity in all aspects of its operations. Through its cutting-edge research and dedication to advancing healthcare, Crinetics Pharmaceuticals Inc strives to make a positive impact in the field of pharmaceuticals.

Analyytikot asettavat tällä hetkellä Crinetics Pharmaceuticals-osakkeelle keskimääräisen tavoitehinnan 84,86 USD (mediaani: 85,00 USD), mikä merkitsee −0,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.

Crinetics Pharmaceuticals Analyytikkojen kursstavoitteet 2026

20 analyytikkoa arvioi tällä hetkellä Crinetics Pharmaceuticals-osaketta: 6 suosittaa ostoa, 14 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Crinetics Pharmaceuticals-yhtiöltä 76,87 M USD liikevaihtoa ja −4,62 USD osakekohtaista tulosta.

Crinetics Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Crinetics Pharmaceuticals-osake noteerataan hintaan 76,12 EUR (84,95 USD).

Crinetics Pharmaceuticals-osake (CRNX) on listattuna 3 pörssissä, muun muassa: NASDAQ (CRNX), Frankfurt (6Z4.F), München (6Z4.MU).

Crinetics Pharmaceuticals Inc is a pharmaceutical company focused on developing novel treatments for certain diseases. The company is based in San Diego, California and was founded in 2008. Crinetics is listed on the NASDAQ and has a market value of approximately $444 million. The business model of Crinetics is based on the discovery and development of innovative therapies for rare diseases that currently lack adequate treatment options. The company focuses on peptide therapeutics that help regulate critical biological functions by stimulating specific hormone receptors. Crinetics has various types of peptide therapeutics in its portfolio, with a focus on four main areas: endocrine disorders, oncology, neurology, and metabolic disorders. The endocrine division aims to target various hormonal dysfunctions. One key product in this division is Lanreotide Depot (formerly CRN00808), which is intended for the treatment of acromegalic patients. Acromegaly is a rare disease caused by overproduction of growth hormone. Lanreotide Depot is currently in Phase 3 clinical trials and released Phase 2 results last year. Crinetics is also developing new peptide therapeutics for Cushing's syndrome (excess production of cortisol), pituitary hormone deficiency, and other endocrine disorders. In the oncology division, Crinetics focuses on the development of peptides for molecular determination of tumor cells. CRN01941 is a promising peptide therapeutic developed for the detection of neuroendocrine tumors. According to company reports, the molecule demonstrated high sensitivity and specificity for detecting tumor-specific antigens in clinical tests. CRN01941 is currently in Phase 1 clinical trials and shows potential for other types of tumors, according to Crinetics. The neurology division includes peptide therapeutics for the treatment of schizoaffective disorders, hyperactivity, and Tourette syndrome. CRN04894 is a peptide therapeutic that shows promising results in the selection process of dopamine receptors in preclinical studies. It is currently in Phase 1 clinical trials. In the metabolic disorders division, CRN04777 is in Phase 1 testing. It is a treatment for type 2 diabetes that specifically targets the glucagon receptor in the pancreas. Crinetics' business model is focused on the development of novel peptide therapeutics for difficult-to-treat diseases. The company markets its patents for licensing to large pharmaceutical companies or enters partnerships with smaller biotechnology companies. The success of Crinetics will depend on the effectiveness of its peptide therapeutics, which still need to be investigated in clinical trials. In summary, the main goal of Crinetics Pharmaceuticals Inc is to research and develop novel peptide therapeutics for rare and serious diseases. The company has multiple products in various stages of clinical testing and intends to make innovative therapy options more accessible through partnerships with pharmaceutical companies.

odotettu liikevaihto Crinetics Pharmaceuticals on 76,87 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Crinetics Pharmaceuticals on −434,17 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Crinetics Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä −18,40. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Crinetics Pharmaceuticals-osakkeen arvostusta.

Crinetics Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 103,94. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Crinetics Pharmaceuticals-osakkeen arvostuskennuslukuna.

Crinetics Pharmaceuticals:n Eulpool-laatuscore on 5/10.

Crinetics Pharmaceuticals:n ISIN on US22663K1079. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Crinetics Pharmaceuticals:n WKN on A2JQTJ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Crinetics Pharmaceuticals:n ticker on CRNX. Tämä pörssinoteeraus käytetään Crinetics Pharmaceuticals-osakkeiden kauppaan pörssissä.